# Orthofix Medical Inc.: Form 10-Q for the period ended Sep 30, 2021

- Company: [Orthofix Medical Inc.](/companies/ofix.md) (CIK 884624)
- Form: 10-Q
- Filed: 2021-11-05
- Accepted by EDGAR: Nov 5, 2021, 08:21 ET
- Period: 2021-09-30
- Accession: 0001564590-21-054754
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/884624/000156459021054754/ofix-10q_20210930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/884624/000156459021054754/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-07-01 to 2021-09-30 | $112.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2021-01-01 to 2021-09-30 | $339.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2021-07-01 to 2021-09-30 | $28.3m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2021-01-01 to 2021-09-30 | $81.7m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2021-07-01 to 2021-09-30 | $84.1m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2021-01-01 to 2021-09-30 | $257.8m | us-gaap:GrossProfit |
| Research and development | 3 months, 2021-07-01 to 2021-09-30 | $12.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2021-01-01 to 2021-09-30 | $36.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2021-07-01 to 2021-09-30 | −$313.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2021-01-01 to 2021-09-30 | $1.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2021-07-01 to 2021-09-30 | −$364.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2021-01-01 to 2021-09-30 | $1.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-07-01 to 2021-09-30 | −$2.2m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2021-01-01 to 2021-09-30 | −$5.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-07-01 to 2021-09-30 | −$0.11 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2021-01-01 to 2021-09-30 | −$0.28 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-07-01 to 2021-09-30 | −$0.11 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2021-01-01 to 2021-09-30 | −$0.28 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-07-01 to 2021-09-30 | 19,769,823 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2021-01-01 to 2021-09-30 | 19,633,782 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2021-01-01 to 2021-09-30 | $6.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2021-01-01 to 2021-09-30 | $11.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2021-09-30 | $82.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-09-30 | $260.2m | us-gaap:AssetsCurrent |
| Total assets | at 2021-09-30 | $500.4m | us-gaap:Assets |
| Current liabilities | at 2021-09-30 | $80.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-09-30 | $135.6m | us-gaap:Liabilities |
| Shareholders' equity | at 2021-09-30 | $364.8m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 35,922 characters.

The following discussion and analysis of Orthofix Medical Inc.’s (sometimes referred to as “we,” “us” or “our”) financial condition and results of our operations should be read in conjunction with the “Forward-Looking Statements” and our condensed consolidated financial statements and related notes thereto appearing elsewhere in this Form 10-Q.

### Executive Summary

We are a global medical device company with a spine and orthopedics focus. Our mission is to deliver innovative, quality-driven solutions as we partner with health care professionals to improve patient mobility. Headquartered in Lewisville, Texas, our spine and orthopedic products are distributed in more than 60 countries via our sales representatives and distributors. For more information, please visit www.orthofix.com.

Notable financial metrics and achievements in the third quarter of 2021 include the following:

- Net sales of $112.4 million, an increase of 1.3% compared to the prior year
- Double-digit growth over the prior year period for both global Spinal Implants and Orthopedics
- Over 1,000 U.S. surgeons trained and 60,000 M6-C artificial cervical discs implanted worldwide to date
- Launched Opus Mg Set synthetic bone void filler
- Submitted AccelStim PMA application for the healing of fresh fractures

### COVID-19 Update and Outlook

The global COVID-19 pandemic has significantly affected our hospital and physician customers, patients, communities, employees, and business operations. At various points in time, the pandemic has led to the cancellation or deferral of elective surgeries and procedures with certain hospitals, ambulatory surgery centers, and other medical facilities; restrictions on travel; the implementation of physical distancing measures; and the temporary or permanent closure of businesses. At this time, the future trajectory of the COVID-19 pandemic remains uncertain, both in the U.S. and in other markets. Significant progress has been made on therapeutic treatments and the development and distribution of vaccines, though the efficacy, timing, and adoption of various treatments and vaccines continue to be uncertain.

Given these various uncertainties, it is unclear the extent to which lingering slowdowns in elective procedures will affect our business during 2021 and beyond. We expect that the effects of COVID-19 on our business will depend on various factors including (i) the magnitude and length of increased case waves in certain geographies, (ii) the existence of multiple strains or variants of the virus that cause COVID-19, and the effectiveness of treatments and vaccines against such variants, (iii) the comfort level of patients in returning to clinics and hospitals, (iv) the extent to which localized elective surgery shutdowns occur, (v) the unemployment rate’s effect on potential patients lacking medical insurance coverage, (vi) the effects of any supply chain disruption or raw material shortages for key product components, (vii) potential labor shortages for our customers or suppliers, and (viii) general hospital capacity constraints occurring because of the need to treat COVID-19 patients.

### Results of Operations

The following table provides certain items in our condensed consolidated statements of operations and comprehensive income (loss) as a percent of net sales:

|  | Three Months Ended September 30, 2021 (%) | 2020 (%) | Nine Months Ended September 30, 2021 (%) | 2020 (%) |
| --- | ---: | ---: | ---: | ---: |
| Net sales | 100.0 | 100.0 | 100.0 | 100.0 |
| Cost of sales | 25.2 | 23.6 | 24.1 | 25.2 |
| Gross profit | 74.8 | 76.4 | 75.9 | 74.8 |
| Sales and marketing | 49.9 | 47.7 | 48.4 | 52.2 |
| General and administrative | 14.5 | 14.9 | 15.1 | 17.1 |
| Research and development | 11.0 | 9.0 | 10.7 | 9.9 |
| Acquisition-related amortization and remeasurement | (0.3) | 1.0 | 1.4 | (0.9) |
| Operating income (loss) | (0.3) | 3.8 | 0.3 | (3.5) |
| Net income (loss) | (1.9) | 4.2 | (1.6) | 4.1 |

18

### Net Sales by Product Category and Reporting Segment

The following tables provide net sales by major product category by reporting segment:

*(U.S. Dollars, in thousands)*

|  | Three Months Ended September 30, 2021 | 2020 | Percentage Change Reported | Constant Currency |
| --- | ---: | ---: | ---: | ---: |
| Bone Growth Therapies | $45,168 | $47,066 | -4.0% | -4.0% |
| Spinal Implants | 28,151 | 25,505 | 10.4% | 10.2% |
| Biologics | 12,806 | 15,245 | -16.0% | -16.0% |
| Global Spine | 86,125 | 87,816 | -1.9% | -2.0% |
| Global Orthopedics | 26,303 | 23,169 | 13.5% | 12.2% |
| Net sales | $112,428 | $110,985 | 1.3% | 1.0% |

*(U.S. Dollars, in thousands)*

|  | Nine Months Ended September 30, 2021 | 2020 | Percentage Change Reported | Constant Currency |
| --- | ---: | ---: | ---: | ---: |
| Bone Growth Therapies | $137,821 | $120,888 | 14.0% | 14.0% |
| Spinal Implants | 83,943 | 67,025 | 25.2% | 24.4% |
| Biologics | 41,351 | 40,319 | 2.6% | 2.6% |
| Global Spine | 263,115 | 228,232 | 15.3% | 15.0% |
| Global Orthopedics | 76,300 | 60,711 | 25.7% | 20.1% |
| Net sales | $339,415 | $288,943 | 17.5% | 16.1% |

Global Spine

Global Spine offers the following products categories:

- Bone Growth Therapies, which includes our market leading external bone growth stimulators that enhance bone fusion. Global Spine uses distributors and sales representatives to sell and support our Bone Growth Therapy devices and provide associated services to hospitals, healthcare providers, and patients.
- Spinal Implants, which includes a broad portfolio of motion preservation and fixation implant products used in surgical procedures of the spine. Global Spine distributes its Spinal Implant products globally through a network of distributors and sales representatives to sell spine products to hospitals and healthcare providers.
- Biologics, which includes a portfolio of regenerative products and tissue forms that allow physicians to successfully treat a variety of spinal and orthopedic conditions. We market our Biologics tissues to hospitals and healthcare providers, primarily in the U.S., through a network of employed and independent sales representatives that support our Spine and Orthopedic surgeons.

#### Three months ended September 30, 2021 compared to 2020

Net sales decreased $1.7 million or 1.9%

- Bone Growth Therapies net sales decreased $1.9 million or 4.0%, primarily driven by increased COVID-19 related restrictions affecting complex overnight procedures, which are a large part of the patient population receiving Bone Growth Therapy devices, partially offset by growth in PhysioStim devices prescribed for healing non-union orthopedic fractures
- Spinal Implants net sales increased $2.6 million or 10.4%, driven by the growth of our Spine Fixation product line internationally, coupled with the continued growth and adoption of our Motion Preservation product line in the U.S.
- Biologics net sales decreased $2.4 million or 16.0%, primarily driven by a decrease in complex overnight procedure volumes as a result of COVID-19 related restrictions from the Delta variant across portions of the U.S.

#### Nine months ended September 30, 2021 compared to 2020

Net sales increased $34.9 million or 15.3%

- Bone Growth Therapies net sales increased $16.9 million or 14.0%, primarily driven by an increase in gross orders across all sales channels as restrictions associated with the COVID-19 pandemic have lessened, particularly when compared to the second quarter of 2020
- Spinal Implants net sales increased $16.9 million or 25.2%, primarily driven by the continued recovery from the effects of the COVID-19 pandemic within our Spine Fixation product line, both in the U.S. and internationally, and from the continued growth and adoption of our Motion Preservation product line in the U.S.
- Biologics net sales increased $1.0 million or 2.6%, primarily driven by the continued recovery from the effects of the COVID-19 pandemic and an increase in revenues from new distributors added over the last 12 months

Global Orthopedics

Global Orthopedics offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions in adults and children unrelated to the spine. Global Orthopedics distributes its products globally through a network of distributors and sales representatives to sell orthopedic products to hospitals and health providers.

#### Three months ended September 30, 2021 compared to 2020

Net sales increased $3.1 million or 13.5%

- Increased order volumes from our international stocking distributors following prior COVID-19 elective procedure delays
- Continued growth in our FITBONE product line
- Increase of $0.3 million due to changes in foreign currency exchange rates, which had a favorable impact on net sales

#### Nine months ended September 30, 2021 compared to 2020

Net sales increased $15.6 million or 25.7%

- Increase of $12.2 million, primarily driven by the continued recovery from the effects of the COVID-19 pandemic, both in the U.S. and internationally
- Continued growth in our FITBONE product line
- Increase of $3.4 million due to changes in foreign currency exchange rates, which had a favorable impact on net sales

### Gross Profit

*(U.S. Dollars, in thousands)*

|  | Three Months Ended September 30, 2021 | 2020 | % Change | Nine Months Ended September 30, 2021 | 2020 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net sales | $112,428 | $110,985 | 1.3% | $339,415 | $288,943 | 17.5% |
| Cost of sales | 28,307 | 26,243 | 7.9% | 81,660 | 72,818 | 12.1% |
| Gross profit | $84,121 | $84,742 | (0.7%) | $257,755 | $216,125 | 19.3% |
| Gross margin | 74.8% | 76.4% | (1.5%) | 75.9% | 74.8% | 1.1% |

#### Three months ended September 30, 2021 compared to 2020

Gross profit decreased $0.6 million

- Decrease primarily resulting from changes in geography and product mix compared to the prior year
- Decrease of $1.0 million, primarily as a result of a short-term increase in electronic procurement costs caused by a global shortage of semiconductor chips, which are used in certain products
- Partially offset by significant non-cash inventory-related charges in the prior year due to lower procedure volumes, largely as a result of COVID-19

#### Nine months ended September 30, 2021 compared to 2020

Gross profit increased $41.6 million

- Increase primarily due to the continued recovery from the effects of the COVID-19 pandemic as net sales have recovered to levels consistent with periods prior to the COVID-19 pandemic and due to increased absorption of fixed costs when compared to the prior year period
- Increase also a result of significant non-cash inventory-related charges in the prior year due to lower procedure volumes, largely as a result of COVID-19

### Sales and Marketing Expense

*(U.S. Dollars, in thousands)*

|  | Three Months Ended September 30, 2021 | 2020 | % Change | Nine Months Ended September 30, 2021 | 2020 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Sales and marketing | $56,097 | $52,926 | 6.0% | $164,220 | $150,718 | 9.0% |
| As a percentage of net sales | 49.9% | 47.7% | 2.2% | 48.4% | 52.2% | (3.8%) |

#### Three months ended September 30, 2021 compared to 2020

Sales and marketing expense increased $3.2 million

- Increase primarily attributed to expenses for marketing events, trade shows, travel, and other related costs as local COVID-19 restrictions have eased in a number of locations

#### Nine months ended September 30, 2021 compared to 2020

Sales and marketing expense increased $13.5 million

- Increase of $10.9 million in variable compensation expenses as a result of the recovery in net sales
- Increase of $2.7 million in expenses for marketing events, trade shows, travel, and other related costs as local COVID-19 restrictions have eased in a number of locations

### General and Administrative Expense

*(U.S. Dollars, in thousands)*

|  | Three Months Ended September 30, 2021 | 2020 | % Change | Nine Months Ended September 30, 2021 | 2020 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| General and administrative | $16,312 | $16,541 | (1.4%) | $51,091 | $49,453 | 3.3% |
| As a percentage of net sales | 14.5% | 14.9% | (0.4%) | 15.1% | 17.1% | (2.0%) |

#### Three months ended September 30, 2021 compared to 2020

General and administrative expense decreased $0.2 million

- Decrease of $1.4 million due to decreased spending on legal settlements, strategic investments, and succession and transition charges when compared to the prior year period
- Partially offset by an increase of $1.0 million as a result of savings initiatives executed in 2020 in response to the COVID-19 pandemic, including the temporary suspension of our 401(k) match, and restrictions on travel and related expenses and hiring, which are no longer in place for 2021

#### Nine months ended September 30, 2021 compared to 2020

General and administrative expense increased $1.6 million

- Increase largely a result of savings initiatives executed in 2020 in response to the COVID-19 pandemic, such as temporary salary reductions in the U.S., suspension of the 401(k) match, and restrictions on travel and related expenses, which are no longer in place for 2021 and from increased costs of medical claims in 2021

### Research and Development Expense

*(U.S. Dollars, in thousands)*

|  | Three Months Ended September 30, 2021 | 2020 | % Change | Nine Months Ended September 30, 2021 | 2020 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $12,360 | $9,962 | 24.1% | $36,378 | $28,691 | 26.8% |
| As a percentage of net sales | 11.0% | 9.0% | 2.0% | 10.7% | 9.9% | 0.8% |

21

#### Three months ended September 30, 2021 compared to 2020

Research and development expense increased $2.4 million

- Increase of $1.4 million related to costs to comply with recent European Union medical device reporting regulations
- Increase in spending to support our development of new innovative and differentiated products or indications and the integration of certain acquired products and assets into our business
- Increase also a result of savings initiatives executed in 2020 in response to the COVID-19 pandemic, including the temporary suspension of our 401(k) match and restrictions on travel and related expenses, which are no longer in place for 2021

#### Nine months ended September 30, 2021 compared to 2020

Research and development expense increased $7.7 million

- Increase of $4.1 million related to costs to comply with recent European Union medical device reporting regulations
- Increase in spending to support our development of new innovative and differentiated products or indications and the integration of certain acquired products and assets into our business
- Increase also a result of savings initiatives executed in 2020 in response to the COVID-19 pandemic, including temporary salary reductions in the U.S., suspension of the 401(k) match, and restrictions on travel and related expenses, which are no longer in place for 2021

### Acquisition-related Amortization and Remeasurement

*(U.S. Dollars, in thousands)*

|  | Three Months Ended September 30, 2021 | 2020 | % Change | Nine Months Ended September 30, 2021 | 2020 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Acquisition-related amortization and remeasurement | $(335) | $1,138 | (129.4%) | $5,028 | $(2,766) | (281.8%) |
| As a percentage of net sales | (0.3%) | 1.0% | (1.3%) | 1.4% | (0.9%) | 2.3% |

Acquisition-related amortization and remeasurement consists of (i) amortization related to intangible assets acquired through business combinations or asset acquisitions, (ii) the remeasurement of any related contingent consideration arrangement, and (iii) recognized costs associated with acquired in-process research and development assets, which are recognized immediately upon acquisition.

#### Three months ended September 30, 2021 compared to 2020

Acquisition-related amortization and remeasurement decreased $1.5 million

- Decrease of $1.6 million primarily related to the remeasurement of potential future revenue-based milestone payments associated with the Spinal Kinetics acquisition that become due upon achievement of certain revenue targets
- Partially offset by an increase of $0.1 million related to the amortization of intangible assets acquired through business combinations or asset acquisitions

#### Nine months ended September 30, 2021 compared to 2020

Acquisition-related amortization and remeasurement increased $7.8 million

- Increase of $5.5 million primarily related to the remeasurement of potential future revenue-based milestone payments associated with the Spinal Kinetics acquisition that become due upon achievement of certain revenue targets
- Increase of $1.5 million associated with acquired in-process research and development assets, which were recognized immediately upon acquisition
- Increase of $1.1 million related to the amortization of intangible assets acquired through business combinations or asset acquisitions
- Partially offset by a decrease of $0.4 million associated with the reassessment of contingent consideration associated with the acquisition of a former distributor

### Non-operating Income and Expense

*(U.S. Dollars, in thousands)*

|  | Three Months Ended September 30, 2021 | 2020 | % Change | Nine Months Ended September 30, 2021 | 2020 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest expense, net | $(433) | $(731) | (40.8%) | $(1,400) | $(2,055) | (31.9%) |
| Other income (expense), net | (1,789) | 1,817 | (198.5%) | (3,528) | 6,088 | (158.0%) |

22

#### Three months ended September 30, 2021 compared to 2020

Interest expense, net decreased $0.3 million

- Decrease of $0.2 million associated with interest expense incurred in the prior year on our outstanding indebtedness under the secured revolving credit facility

Other income (expense), net decreased $3.6 million

- Decrease of $3.5 million associated with changes in foreign currency exchange rates, as we recorded a non-cash remeasurement loss of $1.6 million in the third quarter of 2021 compared to a gain of $1.9 million in the third quarter of 2020

#### Nine months ended September 30, 2021 compared to 2020

Interest expense, net decreased $0.7 million

- Decrease of $0.8 million associated with interest expense incurred in the prior year on our outstanding indebtedness under the secured revolving credit facility

Other income (expense), net decreased $9.6 million

- Decrease of $5.0 million associated with changes in foreign currency exchange rates, as we recorded a non-cash remeasurement loss of $3.2 million in 2021 compared to a gain of $1.8 million in 2020
- Decrease of $4.7 million attributable to funds received in the prior year from the U.S. Department of Health and Human Services as part of the Provider Relief Fund included within the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”)

### Income Taxes

*(U.S. Dollars, in thousands)*

|  | Three Months Ended September 30, 2021 | 2020 | % Change | Nine Months Ended September 30, 2021 | 2020 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Income tax (benefit) expense | $(364) | $607 | (160.0%) | $1,677 | $(17,833) | (109.4%) |
| Effective tax rate | 14.4% | 11.5% | 2.9% | (43.1%) | 300.3% | (343.4%) |

#### Three months ended September 30, 2021 compared to 2020

The increase in the effective tax rate compared to the prior year period was primarily a result of the following factors:

- Certain losses not benefitted
- Changes in financial benefits not recognized for tax purposes, primarily related to acquisition-related remeasurement

The primary factors affecting our effective tax rate for the third quarter of 2021 are as follows:

- Certain losses not benefitted
- Certain financial expenses not recognized for tax purposes, primarily related to acquisition-related Remeasurement
- Reversal of tax benefits related to restricted stock units that vested in the current period
- Non-deductible executive compensation

#### Nine months ended September 30, 2021 compared to 2020

The decrease in the effective tax rate compared to the prior year period was primarily a result of the following factors:

- Certain losses not benefitted
- Changes in financial benefits not recognized for tax purposes, primarily related to acquisition-related remeasurement
- Decreases in reversal of tax benefits related to certain performance stock units that were forfeited, as well as settlement of certain restricted stock units that vested
- Decreases in benefits related to statute expirations for previously unrecognized tax benefits

The primary factors affecting our effective tax rate for the nine months ended September 30, 2021 are as follows:

- Certain losses not benefitted
- Certain financial benefits not recognized for tax purposes, primarily related to acquisition-related remeasurement
- Reversal of tax benefits related to certain performance stock units that were forfeited, as well as settlement of certain restricted stock units that vested
- Non-deductible executive compensation
- Favorable tax ruling related to certain previously unrecognized tax benefits

### Segment Review

Our business is managed through two reporting segments: Global Spine and Global Orthopedics. The primary metric used in managing the business by segment is EBITDA (which is described further in Note 11 to the Notes to the Unaudited Condensed Consolidated Financial Statements contained herein). The following table presents EBITDA by segment and reconciles consolidated EBITDA to income (loss) before income taxes:

*(U.S. Dollars, in thousands)*

|  | Three Months Ended September 30, 2021 | 2020 | Nine Months Ended September 30, 2021 | 2020 |
| --- | ---: | ---: | ---: | ---: |
| Global Spine | $13,908 | $19,960 | $44,835 | $38,670 |
| Global Orthopedics | (196) | 1,258 | (650) | (3,995) |
| Corporate | (8,663) | (6,196) | (24,522) | (16,259) |
| Total EBITDA | $5,049 | $15,022 | $19,663 | $18,416 |
| Depreciation and amortization | (7,151) | (9,030) | (22,153) | (22,299) |
| Interest expense, net | (433) | (731) | (1,400) | (2,055) |
| Income (loss) before income taxes | $(2,535) | $5,261 | $(3,890) | $(5,938) |

### Liquidity and Capital Resources

Cash, cash equivalents, and restricted cash at September 30, 2021, totaled $83.2 million compared to $96.8 million at December 31, 2020.

*(U.S. Dollars, in thousands)*

|  | Nine Months Ended September 30, 2021 | 2020 | Change |
| --- | ---: | ---: | ---: |
| Net cash from operating activities | $6,696 | $51,981 | $(45,285) |
| Net cash from investing activities | (14,031) | (42,944) | 28,913 |
| Net cash from financing activities | (5,673) | 583 | (6,256) |
| Effect of exchange rate changes on cash | (598) | 277 | (875) |
| Net change in cash, cash equivalents and restricted cash | $(13,606) | $9,897 | $(23,503) |

The following table presents free cash flow, a non-GAAP financial measure, which is calculated by subtracting capital expenditures from net cash from operating activities:

*(U.S. Dollars, in thousands)*

|  | Nine Months Ended September 30, 2021 | 2020 | Change |
| --- | ---: | ---: | ---: |
| Net cash from operating activities | $6,696 | $51,981 | $(45,285) |
| Capital expenditures | (12,781) | (12,704) | (77) |
| Free cash flow | $(6,085) | $39,277 | $(45,362) |

### Operating Activities

Cash flows from operating activities decreased $45.3 million

- Decrease in net income of $17.5 million
- Net increase of $10.1 million for non-cash gains and losses, largely related to changes in fair value of contingent consideration and deferred income taxes
- Net decrease of $38.0 million relating to changes in working capital accounts, primarily attributable to other current liabilities, accounts receivable, and changes in our contract liability associated with the CMS Accelerated and Advance Payment Program

Two of our primary working capital accounts are accounts receivable and inventory. Days sales in receivables were 56 days at September 30, 2021 compared to 61 days at September 30, 2020. Inventory turns increased to 1.3 times as of September 30, 2021 compared to 1.2 times as of September 30, 2020.

### Investing Activities

Cash flows from investing activities increased $28.9 million

- Increase of $18.0 million associated with cash paid in March 2020 to acquire assets associated with the FITBONE intramedullary lengthening system for limb lengthening of the femur and tibia bones
- Increase of $6.0 million associated with cash paid for acquisitions
- Increase of $5.0 million associated with our purchase of preferred stock of Neo Medical SA in 2020

### Financing Activities

Cash flows from financing activities decreased $6.3 million

- Decrease of $8.4 million associated with cash paid for the achievement of a revenue-based milestone associated with the Spinal Kinetics acquisition; the milestone payment totaled $15.0 million with a portion of the payment reflected in both operating and financing activities
- Partially offset by an increase in net proceeds of $2.2 million from the issuance of common shares

#### Credit Facilities

As of September 30, 2021, we had no borrowings outstanding under the secured revolving credit facility. In addition, we had no borrowings outstanding under on our €5.5 million ($6.4 million) available lines of credit in Italy. We were in compliance with all required financial covenants as of September 30, 2021.

### Other

For information regarding contingencies, see Note 8 to the Notes to the Unaudited Condensed Consolidated Financial Statements contained herein.

#### Impact of COVID-19 and the CARES Act on Liquidity and Capital Resources

In March 2020, the CARES Act entered into U.S. federal law, which provided emergency assistance and health care for individuals, families, and businesses affected by the COVID-19 pandemic.

In April 2020, we received $13.9 million in funds from the CMS Accelerated and Advance Payment Program to increase cash flow to providers of services and suppliers impacted by the COVID-19 pandemic. Starting in April 2021, Medicare began to recoup 25% of Medicare payments otherwise owed to the provider or supplier for submitted claims. After 11 months, recoupment will increase to 50% for another 6 months. Thus, during these time periods, rather than receiving the full amount of payment for newly submitted claims, the Company’s outstanding accelerated / advance payment balance will be reduced by the recoupment amount until the full balance has been repaid. As of September 30, 2021, the balance of the contract liability associated with the Accelerated and Advance Payment Program of the CARES Act totaled $7.9 million. The Company has classified the entire balance of this contract liability within other current liabilities based upon the Company’s estimates of when such funds will be recouped.

Further, as part of the CARES Act, we were permitted to defer all employer social security payroll tax payments through December 31, 2020, such that 50% of the taxes would be deferred until December 31, 2021, with the remaining 50% deferred until December 31, 2022. As of December 31, 2020, the Company had deferred $0.6 million in social security payroll tax payments under this program. All deferred tax payments were repaid in January 2021. As of September 30, 2021, we have no deferred balance associated with this program.

#### Spinal Kinetics Contingent Consideration

Per the terms of the acquisition agreement under which we acquired Spinal Kinetics, we agreed to make contingent milestone payments of up to $60.0 million in cash to former Spinal Kinetics’ shareholders. One milestone payment, which was for $15.0 million, became due upon FDA approval of Spinal Kinetics’ M6-C artificial cervical disc (the “FDA Milestone”). The FDA Milestone was achieved and paid in 2019. A second milestone payment, totaling $15.0 million, was achieved in the first quarter of 2021 and paid in the second quarter of 2021 upon meeting certain net sales targets.

The remaining milestone payment is a revenue-based milestone payment of $30.0 million in connection with future sales of the acquired artificial discs. The fair value of the contingent consideration arrangement as of September 30, 2021, was $18.4 million; however, the actual amount ultimately paid could be higher or lower than the fair value of the contingent consideration (ultimate payment will either be $30.0 million or the liability will be reversed if the milestone is not met within the required timeline). As of

September 30, 2021, we classified the remaining contingent consideration liability within other long-term liabilities. For additional discussion of this matter, see Note 7 of the Notes to the Unaudited Condensed Consolidated Financial Statements.

#### FITBONE Asset Acquisition

In February 2020, we entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Wittenstein SE (“Wittenstein”), a privately-held German-based company, to acquire assets associated with the FITBONE intramedullary lengthening system for limb lengthening of the femur and tibia bones. At the time of the acquisition, we also entered into a Contract Manufacturing and Supply Agreement (“CMSA”) with Wittenstein. The CMSA with Wittenstein has an initial term of up to two years to manufacture the FITBONE product line. As consideration for the CMSA, we will pay $2.0 million to Wittenstein at the conclusion of the agreement if certain conditions are met in relation to the prompt delivery of manufactured products. This payment is expected to be made in the first quarter of 2022.

#### Neo Medical Convertible Loan

In October 2020, we entered into a Convertible Loan Agreement (the “Convertible Loan”) with Neo Medical SA, a privately held Swiss-based Medtech company (“Neo Medical”), whereby we loaned CHF 4.6 million to Neo Medical. The loan bears interest at 8.0%, with interest due semi-annually. The Convertible Loan matures in October 2024; however, if a change in control of Neo Medical occurs prior to maturity, the Convertible Loan shall become immediately due upon such event.

#### Related Party Transaction

On February 2, 2021, we entered into a technology assignment and royalty agreement with a medical device technology company partially owned and controlled by the wife of President and Chief Executive Officer, Jon Serbousek, whereby we acquired the intellectual property rights to certain assets for consideration of up to $10.0 million. Consideration was comprised of $1.0 million due at signing and $9.0 million in contingent consideration, dependent upon multiple milestones, such as receipt of 510(k) clearance or the attainment of certain net sales targets. For additional discussion regarding this transaction, see Note 3 of the Notes to the Unaudited Condensed Consolidated Financial Statements.

#### IGEA S.p.A Exclusive License and Distribution Agreement

On April 7, 2021, we entered into an Exclusive License and Distribution Agreement (the “License Agreement”) with IGEA S.p.A (“IGEA”), an Italian manufacturer and distributor of bone and cartilage stimulation systems. Per the terms of the License Agreement, we will have the exclusive right to sell IGEA products in the U.S. and Canada. As consideration for the License Agreement, we agreed to pay up to $4.0 million, of which $0.5 million was paid in the second quarter of 2021, with certain payments contingent upon achieving an FDA milestone. The License Agreement also includes certain minimum purchase requirements.

#### Brazil

In September 2019, in relation to an ongoing legal dispute with a former Brazilian distributor, approximately $0.5 million (based upon foreign exchange rates as of September 30, 2021) of our cash in Brazil was frozen upon request to satisfy a judgment. Although we are appealing the judgment, this cash has been reclassified to restricted cash. As of September 30, 2021, we have an accrual of $0.8 million related to this matter, which is classified within other current liabilities

### Off-balance Sheet Arrangements

As of September 30, 2021, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, cash flows, liquidity, capital expenditures or capital resources that are material to investors.

### Contractual Obligations

There have been no material changes in any of our material contractual obligations as disclosed in our Form 10-K for the year ended December 31, 2020.

### Critical Accounting Estimates

Our discussion of operating results is based upon the condensed consolidated financial statements and accompanying notes. The preparation of these statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Our critical accounting estimates are detailed in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2020. There have been no significant changes to our critical accounting estimates.

### Recently Issued Accounting Pronouncements

See Note 2 of the Notes to the Unaudited Condensed Consolidated Financial Statements for detailed information regarding the status of recently issued or adopted accounting pronouncements. As of September 30, 2021, we do not expect any of the issued Accounting Standards Updates to materially affect our condensed consolidated financial statements upon adoption.

### Non-GAAP Financial Measures

We believe that providing non-GAAP financial measures that exclude certain items provides investors with greater transparency to the information used by senior management in its financial and operational decision-making. We believe it is important to provide investors with the same non-GAAP metrics used to supplement information regarding the performance and underlying trends of our business operations in order to facilitate comparisons to historical operating results and internally evaluate the effectiveness of our operating strategies. Disclosure of these non-GAAP financial measures also facilitates comparisons of our underlying operating performance with other companies in the industry that also supplement their GAAP results with non-GAAP financial measures.

The non-GAAP financial measures used in this filing may have limitations as analytical tools, and should not be considered in isolation or as a replacement for GAAP financial measures. Some of the limitations associated with the use of these non-GAAP financial measures are that they exclude items that reflect an economic cost that can have a material effect on cash flows.

#### Constant Currency

Constant currency is calculated by using foreign currency rates from the comparable, prior-year period, to present net sales at comparable rates. Constant currency can be presented for numerous GAAP measures, but is most commonly used by management to analyze net sales without the impact of changes in foreign currency rates.

#### EBITDA

EBITDA is a non-GAAP metric defined as earnings before interest income (expense), income taxes, depreciation, and amortization. EBITDA is the primary metric used by our Chief Operating Decision Maker in managing the business.

#### Free Cash Flow

Free cash flow is calculated by subtracting capital expenditures from net cash from operating activities. Management uses free cash flow as an important indicator of how much cash is generated or used by our normal business operations, including capital expenditures. Management uses free cash flow as a measure of progress on its capital efficiency and cash flow initiatives.

## Market risk

As filed, 123 characters.

There have been no material changes to our market risks as disclosed in our Form 10-K for the year ended December 31, 2020.

## Controls and procedures

As filed, 1,489 characters.

### Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) designed to provide reasonable assurance that the information required to be disclosed in reports filed or submitted under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. These include controls and procedures designed to ensure that this information is accumulated and communicated to management, including our President and Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Management, with the participation of the President and Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2021. Based on this evaluation, our President and Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 30, 2021.

### Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting, known to the President and Chief Executive Officer or the Chief Financial Officer that occurred for the quarterly period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 1,920 characters.

The following risk factors supplement and should be read in conjunction with those contained in the risk factors disclosed in the “Risk Factors” section of our Form 10-K for the year ended December 31, 2020.

*The COVID-19 pandemic and related supply chain and raw material disruptions could have a continuing material impact on our global operations and the operations of our supply chain, which could adversely impact our business results and financial condition.*

We rely on a limited number of suppliers to manufacture or supply certain products or components. In the event of interruption within our supply chain, or global shortages of key supplies or components, we may not be able to increase capacity from other sources or develop alternative or secondary sources without incurring material additional costs and/or substantial delays. For example, the COVID-19 pandemic has led to a global shortage of semiconductor chips, which are used in certain of our products. This shortage appears primarily to have been caused by manufacturers experiencing shutdowns or slowdowns during the pandemic, and it may take several fiscal quarters or longer for normalized capacity to return. In addition, limitations in key raw material supplies could also cause semiconductor chip and other component shortages to continue. To the extent it continues, or more shortages are experienced, particularly on a longer term basis, this could adversely affect our ability to procure such components and manufacture certain of our products or it could require us to redesign any affected products in order to incorporate more readily available components, which may require additional regulatory testing and approvals. Thus, our business could be adversely affected in a significant manner if one or more of our suppliers are impacted by any interruption at a particular location or in relation to a particular material or component.

Filed Nov 5, 2021.
Source: SEC EDGAR, the filing index for accession 0001564590-21-054754. Last ingested by Listed: Nov 13, 2026, 17:00 ET. No prices; not investment advice.
